How Does The NIA-AA Framework Measure Up Against Real Data?
Researchers are applying the proposed 2018 NIA-AA diagnostic criteria to three large, standing cohorts. How did the research framework perform?
ALL NEWS
463 RESULTS
Sort By:
- Most Recent
- Most Commented
Could a Blood Test for Tau Diagnose Alzheimer’s Disease?
An ultrasensitive assay picked up elevated concentrations of N-terminal tau fragments in the blood of people with AD.
Deadline to Weigh In on New Biomarker Guidance Approaches
Stakeholders have until February 11 to comment on draft FDA guidance for biomarker qualification.
Neurofilament in Blood Foretells Early Onset Alzheimer’s
In familial Alzheimer’s disease, rise in NfL in the blood precedes disease onset by 16 years.
Midlife Peripheral Inflammation May Drive Later Cognitive Decline
A longitudinal study finds that middle-aged people with the highest levels of inflammation markers in their blood succumb to the greatest cognitive decline over the next 20 years.
DIAN and ADNI Data Say Familial and Sporadic AD Converge
A comparison of these large data sets shows that while the two forms of Alzheimer’s disease have separate triggers, they follow the same course and are much more similar than different.
Consortium to Seek Biomarkers for Vascular Cognitive Impairment
NIH funds a five-year project to validate biomarkers for clinical trials.
Monogenetic and Sporadic Alzheimer’s Disease: Same or Different?
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
Neurofilament Light Chain: A Useful Marker for AD Progression?
The protein creeps up in the cerebrospinal fluid as the disease worsens.
London: What, No Argument? Speakers Agree on Trials for Familial AD
Part 2 of Alzforum’s coverage continues with what scientists from inside and outside DIAN said about the prospect of such pre-symptomatic trials...
In Big Picture, Familial AD’s Biomarker Data Resemble LOAD
Researchers with eyes peeled toward prodromal AD probably see the diagram of the field’s five most validated markers in their sleep...
Keystone: TBI—Learning From Markers, Models, and Diseases
Injury to the brain, even what might be considered mild, can have devastating consequences on brain physiology...
Geneva: Biomarker News Morsels Amid Immunotherapy Review
Advances in therapy saw little sprigs of news pop up in talks that otherwise took stock of the current status of immunotherapy as one of the major new approaches...
Uppsala: Immunotherapy and Biomarkers Take Center Stage
In addition to immunotherapy, a meeting in Uppsala, Sweden, focused on recent progress in the development of novel disease biomarkers...
Translational Biomarkers in Alzheimer Disease Research, Part 3
This is part 3 of a 5-part series. See also <a href="/news/conference-coverage/translational-biomarkers-alzheimer-disease-research-part-1">part 1</a> and <a href="/news/conference-coverage/translational-biomarkers-alzheimer-disease-research-part-2">part 2</a>...